https://www.oakneepainrelief.com/durolane/

First 1699 Last

Share
Profile

Follow
ronnie999

455 Posts.

46

08/06/21

15:57

Post #: 53719748
Share

Originally posted by WRpar20 ↑

Afternoon all,

I went to see my orthopedic surgeon today in regards to OA in my knee. I told him I have had intermittent dull pain in my knee and asked whether he had heard of PPS. He said he had, and that his daughter is a vet. Apparently his daughter often teases him about how they can get dogs, cats and horses up and running in no time with PPS injections whilst humans suffer continual pain and quite often the only resort is to have surgery with knee replacements and alike. He had not heard of Paradigm nor did he know that the drug was going through clinical trials.

This aside, he is hopeful that the clinical trials are successful and that he can bring pain relief and potential DMOB to his patients.

Given the timelines for the clinical trials and given all goes well and gets approved we know it is not until 2024 that we will likely be able to access PPS for use. However, he did say that there were other alternatives until this time and mentioned the drug 'Durolane' - a drug administered locally within the knee requiring only one injection. The drug aims to support or lubricate the joint in line with synovial fluid. It seems that this has been being used since 2001 and my doctor believes that his patients have received some great results from it for periods of up to 8 months. I tried to do a quick search on here but my tech skills are pretty low. I am sure it has been covered somewhere in regards to what the differences are and whether or not Zilosul is a competitor and how can they gain market share. I understand DMOB is probably the main factor here but besides DMOB considering this we do not have the results from this trial yet.

Further, has anyone had any experience taking Durolane and found that it gave significant relief or found themselves doing activity they have not been able to do with previous pain?

Thanks in advance to anyone that can provide any information on the matter

Expand

https://www.oakneepainrelief.com/durolane/

PAR Price at posting: $2.11 Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 2,730 more messages in this thread...

First 1699 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.5¢		Change 0.005(2.50%)		Mkt cap ! $71.79M

Open	High	Low	Value	Volume
20.0¢	20.5¢	19.5¢	$180.1K	900.5K

Buyers (Bids)

No.	Vol.	Price($)
3	5738	20.5¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	48719	10

View Market Depth

No.	Vol.	Price($)
4	52139	0.205
6	78011	0.200
9	137765	0.195
22	304813	0.190
6	176420	0.185

Price($)	Vol.	No.
0.210	48719	10
0.215	147333	6
0.220	66066	7
0.225	34604	4
0.230	18834	3

Last trade - 14.35pm 07/10/2024 (20 minute delay)

PAR (ASX) Chart

https://www.oakneepainrelief.com/durolane/

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

https://www.oakneepainrelief.com/durolane/

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News